

A Short Review on Gynaecology Cancer

Rishu*

M.Sc Medical Biotechnology, Panjabi university, Dolphin PG College of Life Sciences ,Chandigarh

Research Article

Received: 30/08/2016
Accepted: 03/09/2016
Published: 13/09/2016

*For Correspondence

Rishu, Department of Medical Biotechnology, Dolphin PG College of Life Sciences, Chandigarh, Tel: 7032424881.

Email:

rishu.thakur1810@gmail.com

Keywords: Cervical, Disease, Ovarian, endometrial, bladder

ABSTRACT

Gynecologic tumors are the uncontrolled development and spread of anomalous cells starting in the female regenerative organs, including the cervix, ovaries, uterus, fallopian tubes, vagina and vulva. Ovarian growth for the most part positions fifth in disease passings among ladies. It is regularly alluded to as the quiet executioner as it causes not very many manifestations. The danger of ovarian malignancy increments with age, and family history of the illness is a standout amongst the most noteworthy danger variables.

Cervical growth is viewed as a standout amongst the most preventable gynaecologic diseases with the improvement of another immunization to avoid HPV contamination in young ladies. HPV contamination causes the lion's share of cervical tumors.

Endometrial malignancy is the most well-known growth of the female conceptive organs and danger elements incorporate heftiness, hypertension, diabetes, improper estragon use, tamoxifen use, and late menopause.

INTRODUCTION

Tumor has turned into an essential Public Health Problem with more than 800,000 new cases happening each year, and is one of the ten driving reasons for death in India. Anytime of time, it is evaluated that there are about 2.5 million cases in the nation with almost 400,000 passing's happening because of malignancy. Growth occurrence in India is assessed to associate with 70-90 for every 100,000 populace. Disease registries have likewise highlighted that more than 80% of malignancy in females happen in the age gathering of 35-64, and 3.5% to 4.5% in adolescence, in this way recommending the effect of growth as a noteworthy general wellbeing issue in the most beneficial age bunch. Almost 1,500,000 individuals require offices for analysis, treatment and follow-up at a given time.

TYPES OF CANCER

Cervical

Cervical tumor begins in a lady's cervix, which is the lower, contract part of the uterus. The uterus holds the developing hatchling amid pregnancy. The cervix interfaces the lower part of the uterus to the vagina and, with the vagina, shapes the birth channel.

Fallopian tube

Fallopian Tube Cancer. Fallopian tube tumor, otherwise called tubal disease, creates in the fallopian tubes that interface the ovaries and the uterus. It is extremely uncommon and represents just 1 percent to 2 percent of every gynecologic tumor.

Ovarian

Ovarian tumor is a growth that structures in an ovary. It results in strange cells that can attack or spread to different parts of the body. When this procedure starts, there might be no or just dubious manifestations. Side effects turn out to be more recognizable as the disease advances. These side effects may incorporate bloating, pelvic agony, stomach swelling, and loss of ravenousness, among others. Regular regions to which the malignancy may spread incorporate the coating of the midriff, covering of the inside and bladder, lymph hubs, lungs, and liver.

Uterine

The uterus is an empty, strong organ where an embryo develops. Uterine tumor can begin in various parts of the uterus. Most uterine growths begin in the endometrium (the internal coating of the uterus). This is called endometrial disease. Most endometrial growths are adenocarcinomas (diseases that start in cells that make bodily fluid and other liquid

Vaginal

Vaginal tumor is a malady in which threatening (growth) cells structure in the vagina. Age and being presented to the medication DES (diethylstilbestrol) before birth influence a lady's danger of vaginal disease. Signs and side effects of vaginal disease incorporate torment or unusual vaginal dying.

DIAGNOSTIC TESTS

New treatments are being assessed by gynecologic disease masters at Johns Hopkins, early location and conclusion remains a lady's best chance to treat gynecologic growths. Routine yearly gynecologic examinations are the primary line of resistance. Cervical disease is the main gynecologic tumor that, in many cases, can be kept away from by consistent Pap test screening. The Pap test, a straightforward methodology that can be performed amid routine gynecologic visits, recognizes pre-carcinogenic changes in the cervix. Taking after the advancement of this test, death rates from cervical tumor have dropped by more than 70 percent. Still, a large number of U.S. ladies will kick the bucket yearly from cervical malignancy.

GYNECOLOGIC CANCER SYMPTOMS

- Pressure, totality or agony in the pelvis,
- Abdominal bloating,
- abnormal dying
- Painful pee
- Pain amid intercourse
- Changes in entrail and bladder designs that proceed and/or decline.

Generally, ovarian malignancy does not bring about numerous early signs until the growth develops. Early cervical malignancy additionally does not bring about numerous side effects, but rather when the tumor spreads, ladies may encounter strange draining and expanded vaginal release. Irregular draining is the most well-known manifestation of endometrial growth. Different side effects may incorporate troublesome or difficult pee, torment amid intercourse, or torment in the pelvic region

GYNECOLOGIC CANCER TREATMENTS

Surgery, radiation, hormone treatment or chemotherapy might be utilized to treat gynecologic malignancies. The treatment arrangement relies on upon various elements, including the sort and phase of sickness, the lady's age and her general wellbeing.

Surgery

Surgery is the most seasoned and, maybe, the most broadly honed type of growth treatment. About sixty percent of all malignancy patients experience some type of surgical treatment. The explanation behind this is frequently the most straightforward approach to dispose of disease is to simply expel it surgically. Surgery is frequently utilized as a part of conjunction with radiation treatment and/or chemotherapy. Before seeking after surgical treatment, you ought to dependably acquire a second restorative conclusion from an alternate gynecologic oncologist. You might need to look for extra conclusions from a radiation oncologist and/or a therapeutic oncologist to think about, differentiation and pick your most ideal choice from this exhaustive cluster of feelings. Surgery is permanent—therefore, it is basic for consideration suppliers to direct exhaustive lab and indicative work before and amid surgery, to guarantee the malignancy is bound to the surgical zone.

Gynecologic surgical methods

Total Hysterectomy: An aggregate hysterectomy is an inpatient method that includes the surgical evacuation of your uterus, cervix, both ovaries and both fallopian tubes. The specialist may likewise expel lymph hubs from your pelvis and mid-region to test for malignant cells.

Radical Hysterectomy: A radical hysterectomy is an inpatient method that incorporates the surgical evacuation of your uterus, cervix, fallopian tubes, ovaries and part of the vagina. The specialist likewise expels lymph hubs from the encompassing region to test for carcinogenic cells.

Laparoscopic Hysterectomy: A laparoscopic hysterectomy is called an "insignificantly obtrusive" methodology that is led on an inpatient premise. Utilizing a laparoscope—a seeing instrument embedded through three or four little incisions—the specialist separates and evacuates your uterus, fallopian tubes and ovaries through one of the other existing entry points. Specialists may likewise expel encompassing lymph hubs to test for dangerous cells.

Loop Electrosurgical Excision Procedure (LEEP): A LEEP is an outpatient technique utilizing an electrically charged wire circle to cut off the peripheral layer of your cervix.

Surgical Conization: Surgical conization is an outpatient technique including the evacuation of a cone-formed area of tissue from your cervix. Specialists may utilize either a surgical blade or a laser to evacuate this tissue.

Radiation Therapy

There are two sorts of radiation therapy—internal and outside. Both structures light confined areas of your body. Outside radiation works by using powerful X-beams, gamma beams or electron shaft radiation to target and obliterate quickly separating dangerous cells situated in a particular site of your body. Inward radiation utilizes minor radioactive seeds, pellets, containers or needles to convey an inside dosage of radiation for a foreordained timeframe. A few types of gynecologic radiation treatment for all time harm the ovaries, restraining your characteristic capacity to create the female sex hormone estrogen. Since menopause—the stage in a lady's life when the ovaries steadily emit less and less estrogen—does not more often than not happen until a lady's late 40s or mid 50s, pre-menopausal ladies accepting radiation treatment for gynecologic diseases may require hormone substitution treatment (HRT). HRT supplies your body with the estrogen levels important to avert bone consumption and coronary illness, and regular menopausal side effects like hot flashes and night sweats.

3D Conformal Radiation Therapy : 3-D conformal radiation treatment is an outer type of radiation treatment using processed tomography (CT) wanting to picture and reproduce the tumor and encompassing typical tissues in three measurements utilizing a PC program. This innovation permits the radiation oncologist to acclimate the radiation beam(s) to particular target ranges. Since the radiation shafts are unequivocally engaged, your close-by ordinary tissue is saved.

Intensity Modulated Radiation Therapy (IMRT): IMRT speaks to a propelled type of outside 3D conformal radiation treatment. Utilizing an effective PC system to arrange the exact measurements of radiation in three measurements, radiation oncologists may differ the force and conformance of pencil-slight radiation bars onto particular destructive destinations. Our growth specialists let us know they can utilize higher radiation measurements than conventional

strategies would permit in these ranges, but then extra a greater amount of the encompassing solid tissue, contrasted with standard radiation treatment.

Gynecologic High-Dose-Rate (HDR) Brachytherapy: Used most usually in the postoperative treatment of endometrial and cervical malignancy and ordinarily joined with outer pillar radiation, gynecologic HDR brachytherapy places the radiation inside your tumor, firmly engaged inside the site of the growth. This system guarantees the greatest radiation measurements is given where you require it most, while permitting little radiation to achieve the solid encompassing tissue. By and large, brachytherapy is a powerful contrasting option to surgical evacuation of a tumor and the influenced organ. Likewise, the whole treatment takes one and a half days rather than 57 weeks.

Chemotherapy

Chemotherapy is a wide term identifying with a gathering of solutions intended to harm a malignancy cell's capacity to develop. Restorative Oncologists—doctors who spend significant time in treating tumor with various sorts of medications and chemotherapy—oversee this part of malignancy treatment. You may get chemotherapy orally or through an intravenous (IV) organization. Dissimilar to radiation treatment, routine chemotherapy is a systemic treatment conveyed all through your whole body by the circulation system. New medicines control reactions and, with the best possible thorough group of specialists, the symptoms can regularly be overseen and minimized. Chemotherapy is regularly utilized as a part of conjunction with surgery and/or radiation treatment.

Intraperitoneal Chemotherapy : Intraperitoneal Chemotherapy includes flooding the peritoneal sac—the lining inside your abdomen—with chemotherapy. Utilized especially as a part of the treatment of ovarian tumor, intraperitoneal chemotherapy pools a concentrated measure of warmed chemotherapeutic operator in the peritoneal sac, "washing" the region in a chemotherapy shower.

Fractionated Dose Chemotherapy : This technique contrasts from customary chemotherapy in that the aggregate measurements of your chemotherapy is broken into littler sums and directed over a five-day time span, as opposed to a solitary bigger dosage. This helps you by amplifying the measurement force and uncovering malignancy cells inside your body to the medications for a more extended timeframe, while lessening a portion of the obnoxious reactions of chemotherapy.

Intra-blood vessel Infusion of Chemotherapy: This treatment can convey a higher reaction rate than chemotherapy that is given orally or intravenously. It can be utilized for any tumor with a blood supply that can be secluded by experienced angiographers. In the event that you have repetitive cervical tumor, you might be a contender for intra-blood vessel mixture. This system conveys high measurements of chemotherapy medications straightforwardly to your tumor, through a catheter precisely guided into the vein that supplies the zone with blood. This causes less harm to sound tissue in different ranges of your body.

Developing Therapies

In the hands of a talented doctor, rising treatments speak to promising new treatment alternatives accessible in select healing centers the nation over. Immunotherapy, bone marrow transplant (BMT), hormonal treatment, photodynamic treatment (PDT), hyperthermia and blood vessel embolization represent a portion of the more noticeable rising treatments now accessible to you. You and your doctors may swing to rising treatments in three distinct circumstances: in the wake of depleting all surgical, radiation and/or chemotherapy alternatives; when your doctor decides customary treatments will no more enhance your condition; or when you may profit by a rising treatment utilized as a part of conjunction with other ordinary medicines.

Aside from the Four primary treatment modalities, you ought to likewise consider torment administration and palliative consideration administrations.

Palliative Care: Palliative Care is a particular type of prescription, centered after reducing agony, queasiness or any number of opposite side influences you may encounter amid treatment. Couple of healing centers offer a committed Palliative Care Department—but paying little mind to this pattern, viably dealing with your torment is vital for ideal treatment. Unmanaged torment may meddle with your rest examples, hankering and treatment plan. You ought to ask about the Palliative Care or Pain Management programs accessible in any doctor's facilities you consider for treatment.

CONCLUSION

As a Result of review, we infer that the absence of access to quality consideration remains a noteworthy weight for ladies determined to have gynecologic growths and is a noteworthy point for intercession. From counteractive action and screening (cervical growth) to disease coordinated surgery (ovarian, endometrial, and cervical tumors) receipt of standard of consideration emphatically affects survival. Decrease the danger of growth can be accomplished by extend access to quality medicinal services; upgrade instructive endeavors and familiarity with racial and ethnic inconsistencies; prepare a more differing oncology workforce; incorporate abberations in exploration needs; improve singular patient cooperation in consideration which is a basic stride to wiping out gynecologic tumor differences.

REFERENCES

1. Sahli N, et al. Impact of brachytherapy in the treatment of locally advanced cervical cancer: Results from a single institution. *Gynecol Obstet (Sunnyvale)*. 2016;6:386.
2. Ali CI, et al. Cervical cancer: A health limiting condition. *Gynecol Obstet (Sunnyvale)*. 2016;6:378.
3. Groen RS, et al. Association between shoulder dystocia maneuvers and cervical laceration requiring repair. *Gynecol Obstet (Sunnyvale)*. 2016;6:364.
4. Sahli N, et al. Impact of treatment duration on cervical cancer outcomes: results from a single institution. *Gynecol Obstet (Sunnyvale)*. 2016;6:354.
5. Zoi T, et al. Cervical adenocarcinoma in situ presentation of the case and review of incidence, recurrence rate and therapeutic options. *Gynecol Obstet (Sunnyvale)*. 2015;5:342.
6. ZHeng J, et al. Defective expression of polarity protein Par3 promotes cervical tumorigenesis and metastasis. *Gynecol Obstet (Sunnyvale)*. 2015;5:317.

7. Aliya A, et al. HPV adjunct testing to VIA as an alternative to cytology for cervical cancer screening in Pakistan. *Gynecol Obstet (Sunnyvale)*. 2015;5:295.
8. Begum S, et al. Mobilising women from a low income community to attend cervical cancer screening camps: Insights from a study in an urban slum of Mumbai. *Gynecol Obstet (Sunnyvale)*. 2014;4:197.
9. Fadahunsi OO, et al. Prevalence of high risk oncogenic human papillomavirus types in cervical smears of women attending well woman clinic in Ile Ife, Nigeria. *Gynecol Obstet Sunnyvale*. 2013;3:185.
10. Menczer J, et al. A comparison of Israeli Jewish women with genital warts (*Condilimata Acuminata*) to cervical cancer patients regarding the presence of selected risk factors. *Gynecol Obstet*. 2013;3:174.
11. Da Fonseca AJ, et al. Cost-effectiveness of primary and secondary prevention strategies for cervical cancer in Brazil: A systematic review. *Gynecol Obstet*. 2013;3:169.
12. Thomakos N, et al. Less radical surgery for fertility preservation in patients with early-stage invasive cervical cancer contemporary problematics. *Gynecol Obstet*. 2013;3:165.
13. Ashraf TA, et al. Bipolar vessel sealer versus harmonic scalpel in laparoscopic supracervical hysterectomy. *Gynecol Obstet*. 2012;2:137.
14. Chen JR, et al. Smaller but better? The effort to shrink surgical scale for selected early stage cervical cancer. *Gynecol Obstet*. 2012;2:e108.
15. Obeidat RA, et al. Prevalence of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer in women with post-coital bleeding (PCB) and negative smear: A retrospective study. *Gynecol Obstet*. 2012;2:127.
16. Malapati R, et al. Late mid-trimester pregnancy, advanced bulky cervical cancer, radiation therapy and physician's moral distress: A management dilemma. *Gynecol Obstetric*. 2012;2:114.
17. Zeng Y, et al. Symptom profiles, work productivity and quality of life among Chinese female cancer survivors. *Gynecol Obstet (Sunnyvale)*. 2016;6:357.
18. Mohamad KAA, et al. Visual inspection after acetic acid (VIA) as an alternative screening tool for cancer cervix. *Gynecol Obstet (Sunnyvale)*. 2015;5:336.
19. Chikazawa K, et al. Bevacizumab treatment for recurrent ovarian cancer with isolated metastasis to the lymph node. *Gynecol Obstet (Sunnyvale)*. 2015;5:329.
20. Rotschild G, et al. Single incision laparoscopy and vaginal hysterectomy for the approach of endometrial cancer in a morbidly obese patient. *Gynecol Obstet (Sunnyvale)*. 2015;5:313.
21. Schorge JO, et al. Therapeutic innovations in ovarian cancer treatment: The New England perspective. *Gynecol Obstet (Sunnyvale)*. 2015;5:289.
22. Salani R, et al. Assessment of women's knowledge of endometrial cancer. *Gynecol Obstet (Sunnyvale)*. 2014;4:253.
23. Kuroda H, et al. Recurrent cerebral infarctions in a patient with ovarian cancer: A fatal case of Trousseau's syndrome. *Gynecol Obstet (Sunnyvale)*. 2014;4:232.
24. Kobayashi E, et al. Pedunculated sub-serous leiomyosarcoma mimicking ovarian cancer: Case report and review of literature. *Gynecol Obstet*. 2013;3:157.
25. Liu MX, et al. Mechanisms of chemoresistance in human ovarian cancer at a glance. *Gynecol Obstet*. 2012;2:e104.

26. Espino-Strebel EE, et al. Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. *Gynecol Obstetric* 2012;2:115.
27. Fornalik H, et al. Aspirin and warfarin are associated with improved overall survival in medically inoperable endometrial cancer patients treated with radiation therapy. *Gynecol Obstetric*. 2012; S4:002.
28. Shoji Y, et al. Over-expression of Ly6/Plaur domain containing 6b (Lypd6b) in ovarian cancer. *Gynecol Obstetric*. 2011;1:103.
29. Oranratanaphan S, et al. Colonic endometriosis mimicking sigmoid cancer: A case report. *Gynecol Obstetric*. 2011;1:101.
30. Mahendru R, et al. Peripartum cardiomyopathy: Rare albeit significant. *Gynecol Obstet (Sunnyvale)*. 2016;6:e115.
31. Asefa D, et al. Chronic postmenopausal uterine inversion: A case report. *Gynecol Obstet (Sunnyvale)*. 2016;6:384.
32. Samba A, et al. A review of caesarean sections using the ten-group classification system (Robson classification) in the Korle-Bu Teaching Hospital (KBTH), Accra, Ghana. *Gynecol Obstet (Sunnyvale)*. 2016;6:385.
33. Sahli N, et al. Impact of brachytherapy in the treatment of locally advanced cervical cancer: Results from a single institution. *Gynecol Obstet (Sunnyvale)*. 2016;6:386.
34. Iannaccone A, et al. The use of plasma exchange in a very early-onset and life threatening, hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome: A case report. *Gynecol Obstet (Sunnyvale)*. 2016;6:387.
35. Nassar K, et al. Vitamin D and pre-eclampsia. *Gynecol Obstet (Sunnyvale)*. 2016;6:389.
36. Smirnova A, et al. Live birth after *in vitro* maturation of oocytes in a patient with repeated fertilization failure in IVF: A case report. *Gynecol Obstet (Sunnyvale)*. 2016;6:390.
37. Swasti. Evolution of cytoreductive surgery for ovarian cancer – ‘A walk down the memory lane’. *Gynecol Obstet (Sunnyvale)*. 2016;6:e113.
38. Bouzid A, et al. Osteoid metaplasia of the endometrium: A case report and literature review. *Gynecol Obstet (Sunnyvale)*. 2016;6:361.
39. Latheef R, et al. Ewing’s sarcoma of uterus – Case report and review of literature. *Gynecol Obstet (Sunnyvale)*. 2016;6:362.
40. Rao S, et al. A study to find out the prevalence of hypothyroidism among pregnant women visiting ESI Hospital, Sanathnagar, Hyderabad. *Gynecol Obstet (Sunnyvale)*. 2016; 6:363.
41. Groen RS, et al. Association between shoulder dystocia maneuvers and cervical laceration requiring repair. *Gynecol Obstet (Sunnyvale)*. 2016;6:364.
42. Rai S. Impact of co-existent infections on surgical site in cesarean deliveries. *Gynecol Obstet (Sunnyvale)*. 2016;6:365.
43. Lee MH, et al. Prognosis predictors of pelvic inflammatory disease among the hospitalized patients. *Gynecol Obstet (Sunnyvale)*. 2016;6:366.
44. Sahli N, et al. Impact of treatment duration on cervical cancer outcomes: Results from a single institution. *Gynecol Obstet (Sunnyvale)*. 2016;6:354.

45. Denakpo J, et al. Profile, morbidities and symptoms management of menopausal women, in Cotonou. *Gynecol Obstet (Sunnyvale)*. 2016;6:355.
46. Musa A, et al. Determinants of birth preparedness and complication readiness among pregnant woman attending antenatal care at Dilchora Referral Hospital, Dire Dawa City, East Ethiopia. *Gynecol Obstet (Sunnyvale)*. 2016;6:356.
47. Zeng Y, et al. Symptom Profiles, work productivity and quality of life among Chinese female cancer survivors. *Gynecol Obstet (Sunnyvale)*. 2016;6: 357.
48. Vijaylakshmi AR, et al. A prolapsed longitudinal vaginal septum with invaginating cystocele and rectocele: A rare presentation with a unique management. *Gynecol Obstet (Sunnyvale)*. 2016;6: 358.
49. Lee BN, et al. Leiomyosarcoma of the ovary mimicking gastrointestinal stromal tumor originating from small bowel: A case report and literature review. *Gynecol Obstet (Sunnyvale)*. 2016;6: 359.
50. Di H, et al. The role of inflammatory cytokines in the pathogenesis of cerebral palsy. *Gynecol Obstet (Sunnyvale)*. 2016;6:360.
51. Rath TS, et al. The uncharted waters of obstetrics - rupture of non-communicating rudimentary horn pregnancy (Rnhp) in a bicornuate uterus. *Gynecol Obstet (Sunnyvale)*. 2016;6:347.
52. Zilberlicht A, et al. Gullian- Barre syndrome in pregnancy – A case report and review of the literature. *Gynecol Obstet (Sunnyvale)*. 2016;6:348.
53. Pyra K, et al. Embolisation in the therapy of post-partum haemorrhage in a patient with a massive myoma. *Gynecol Obstet (Sunnyvale)*. 2016; 6: 349.
54. Bizjak T, et al. Prevalence and risk factors of uterine fibroids in North-East Slovenia. *Gynecol Obstet (Sunnyvale)*. 2016;6:350.
55. Wu Q, et al. Detection of copy number variants by next-generation sequencing in fetuses with congenital heart disease. *Gynecol Obstet (Sunnyvale)*. 2016;6:351.
56. Nigatu DT, et al. Barriers to contraceptive use among child bearing women in Ambo Town, West Shewa Zone, Oromia Regional State, Ethiopia. *Gynecol Obstet (Sunnyvale)*. 2016;6:352.
57. Sahli N, et al. Cervical cancer: Prognostic and evolution after radiotherapy (Results from a single institution). *Gynecol Obstet (Sunnyvale)*. 2016;6:353.
58. Nebeb GT, et al. Antenatal care utilization in Debre Tabor, North West Ethiopia. *Gynecol Obstet (Sunnyvale)*. 2015;5:339.
59. Desai R, et al. A case of severe tongue bite in eclampsia. *Gynecol Obstet (Sunnyvale)*. 2015;5:340.
60. Imaizumi Y. Infant mortality of zygotic twins and influencing factors in Japan, 1995–2008. *Gynecol Obstet (Sunnyvale)*. 2015;5:341.
61. Zoi T, et al. Cervical adenocarcinoma *in situ* presentation of the case and review of incidence, recurrence rate and therapeutic options. *Gynecol Obstet (Sunnyvale)*. 2015;5:342.
62. Jafarian T, et al. Are beta2-adrenergic receptor gene single-nucleotide polymorphisms associated with polycystic ovary syndrome? A pharmacogenetic study. *Gynecol Obstet (Sunnyvale)*. 2015;5:343.
63. Assefa D, et al. Macrosomia in discordant twin: An out of the box presentation of abnormal growth in dizygotic twin. *Gynecol Obstet (Sunnyvale)*. 2015;5:344.
64. Ridha F, et al. Cystic hygroma of the neck: Prognostic factors and therapeutic implications. *Gynecol Obstet (Sunnyvale)*. 2015;5:345.

65. Amer M, et al. Psoriasis severity is affected by T the lipid profile in Egyptian patients. *Gynecol Obstet (Sunnyvale)*. 2015;5:346.
66. Obossou AAA, et al. Prognostic factors of pregnancy and childbirth in adolescents at the Borgou Regional University Teaching Hospital in Parakou (Benin). *Gynecol Obstet (Sunnyvale)*. 2015;5:332.
67. Tran PL, et al. Delayed interval delivery in multifetal pregnancy: A review and guidelines for management. *Gynecol Obstet (Sunnyvale)*. 2015;5:333.
68. Deng J, et al. Primary human trophoblasts expressing four essential receptors of hepatitis C virus entry but resistance to infection *in vitro*. *Gynecol Obstet (Sunnyvale)*. 2015;5:334.
69. Ding JX, et al. Laparoendoscopic single site myomectomy: without the use of a single port access device. *Gynecol Obstet (Sunnyvale)*. 2015;5:335.
70. Mohamad KAA, et al. Visual inspection after acetic acid (VIA) as an alternative screening tool for cancer cervix. *Gynecol Obstet (Sunnyvale)*. 2015;5:336.
71. Okafor II, et al. Prevalence of couple human immunodeficiency virus (HIV) discordance and prevention of new HIV infection in the negative partner in Enugu, South-East Nigeria. *Gynecol Obstet (Sunnyvale)*. 2015;5:337.
72. Mbamara SU, et al. Successful pregnancy in a woman with chronic kidney disease due to autosomal polycystic disease - A case report. *Gynecol Obstet (Sunnyvale)*. 2015;5:338.
73. Kabibou S, et al. Dysfunctions in the management of severe preeclampsia in a second-level Referral Hospital (Parakou/Benin). *Gynecol Obstet (Sunnyvale)*. 2015;5:324.
74. Short H, et al. A case of sub-acute thyroiditis presenting with oligomenorrhea. *Gynecol Obstet (Sunnyvale)*. 2015;5:325.
75. Andrade AG, et al. How contraception changes in recurrent unintended pregnancy. *Gynecol Obstet (Sunnyvale)*. 2015;5:326.
76. Messerschmidt L, et al. Labia minora reduction – Patients symptoms and satisfaction in short and long term. *Gynecol Obstet (Sunnyvale)*. 2015;5:327.
77. Okafor II, et al. Imperforate hymen presenting with massive hematometra and hematocolpos: A case report. *Gynecol Obstet (Sunnyvale)*. 2015;5:328.
78. Chikazawa K, et al. Bevacizumab treatment for recurrent ovarian cancer with isolated metastasis to the lymph node. *Gynecol Obstet (Sunnyvale)*. 2015;5:329.
79. Kim EK, et al. Day 4 biopsy improves pregnancy outcome comparing to day 3 biopsy in pre-implantation genetic screening. *Gynecol Obstet (Sunnyvale)*. 2015;5:330.
80. Kwon H, et al. Accumulation of vitrified embryos followed by frozen embryo transfer in poor ovarian responders according to Bologna criteria. *Gynecol Obstet (Sunnyvale)*. 2015;5:331.
81. Dile M, et al. Knowledge of obstetric danger signs and its associated factors in Debayilatgin District, Ethiopia: A community based cross sectional study. *Gynecol Obstet (Sunnyvale)*. 2015;5:315.
82. Rubido Valle CD, et al. Ovarian steroid cell tumor associated to endometrial hyperplasia and presenting as post-menopausal vaginal bleeding. *Gynecol Obstet (Sunnyvale)*. 2015;5:316.
83. ZHeng J, et al. Defective expression of polarity protein Par3 promotes cervical tumorigenesis and metastasis. *Gynecol Obstet (Sunnyvale)*. 2015;5:317.

84. Russman C, et al. Spontaneous heterotopic pregnancy: A case report. *Gynecol Obstet (Sunnyvale)*. 2015;5:318.
85. Açıkğöz AS, et al. Fetal abdominal cysts: Prenatal diagnosis and management. *Gynecol Obstet (Sunnyvale)*. 2015;5:319.
86. Rani A, et al. A case of non-communicating uterine horn containing functional endometrium. *Gynecol Obstet (Sunnyvale)*. 2015;5:320.
87. Lete I, et al. A cross-sectional study of the choice of oral estrogen contraceptives in women seeking contraceptive counseling: What type of pill do women prefer after being counseled? *Gynecol Obstet (Sunnyvale)*. 2015;5:321.
88. Wiebe ER, et al. Knowledge and attitudes about contraception and abortion in Canada, US, UK, France and Australia. *Gynecol Obstet (Sunnyvale)*. 2015;5:322.
89. Okeh NO, et al. Knowledge and perception of risks and complications of maternal obesity during pregnancy. *Gynecol Obstet (Sunnyvale)*. 2015;5:323.
90. ile M, et al. Proportion of maternal near misses and associated factors in Referral Hospitals of Amhara regional State, Northwest Ethiopia: Institution based cross sectional study. *Gynecol Obstet (Sunnyvale)*. 2015;5:308.
91. Ma JQ, et al. Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women. *Gynecol Obstet (Sunnyvale)*. 2015;5:309.
92. Girma T, et al. Knowledge, attitude and practices of emergency contraception among female students in preparatory school of East Shoa, Adama, Ethiopia. *Gynecol Obstet (Sunnyvale)*. 2015; 5: 310.
93. Ribeiro VC, et al. Clinical implication of atypical glandular cells; a five years' experience of a single institution in Portugal. *Gynecol Obstet (Sunnyvale)*. 2015;5:311.
94. Zin AAM, et al. Primary vaginal melanoma – Cytohistological correlates and literature reviews. *Gynecol Obstet (Sunnyvale)*. 2015;5:312.
95. Rotschild G, et al. Single incision laparoscopy and vaginal hysterectomy for the approach of endometrial cancer in a morbidly obese patient. *Gynecol Obstet (Sunnyvale)*. 2015;5:313.
96. Lhagadang F, et al. Epidemiological aspects and foeto-maternal complications of malaria at N'Djamena Mother and Child Hospital (Chad). *Gynecol Obstet (Sunnyvale)*. 2015;5:314.
97. Kestane I, et al. The use of risk of malignancy index for adnexal masses. *Gynecol Obstet (Sunnyvale)*. 2014;4:226.
98. Katherine CN, et al. Recurrent ipsilateral cornual pregnancy with high bHCG level successfully treated with single dose of methotrexate injection: A case report. *Gynecol Obstet (Sunnyvale)*. 2014;4:227.
99. Okafor II, et al. Utero-vesical fistula: A case report. *Gynecol Obstet (Sunnyvale)*. 2014;4:228.
100. Takehara K, et al. Primary malignant melanoma of the vagina with a survival of longer than 5 years after recurrence: Case report and review of the literature. *Gynecol Obstet*. 2013; 3:183.